item management s discussion and analysis of financial condition and results of operations overview the company has been principally engaged in the research and development  manufacturing and commercialization of proprietary viscoelastic biological polymers  called hylans  for use in therapeutic medical applications and skin care 
during the past four years  a significant source of revenue for the company has been from certain up front payments relating to corporate license and distribution agreements 
the company expects milestone payments from existing agreements to continue to be an important source of revenues 
the company s business is subject to significant risks 
forward looking comments included herein are subject to and should be read in conjunction with the risk factors section of this form k 
as a significant amount of the company s future revenues may be based on payments from corporate license and distribution agreements  the company s total revenues and net income will fluctuate from quarter to quarter 
some of these fluctuations may be significant and  as a result  quarter to quarter comparisons may not be meaningful 
as of december   the company s accumulated deficit was  a reduction of  from the company s accumulated deficit of  as of december  results of operations for the years ended december  and revenues 
total revenues for the year ended december  were  representing an increase of  or from the same period of net product sales for the year ended december  were  representing an increase of  or over the same period in the increase in product sales was due primarily to the launch of synvisc in the united states and in certain european countries and higher sales of hylaform in certain european countries 
income from licenses  royalties  research contracts and grants were  in  an increase of  or from  and represented of total revenues 
this increase was due primarily to the receipt of up front non refundable fees of  related to the licensing of synvisc for distribution in the united states and certain foreign countries and a  milestone payment from wyeth which was received when the united states fda approved synvisc for marketing in august included in license fees for the year ended december   were non refundable up front and milestone payments from wyeth and bayer of  and  respectively 
included in license fees for the year ended december   were up front non refundable payments from collagen corporation and boehringer ingelheim of  and  respectively 
costs and expenses 
total costs and expenses were  for the year ended december   representing an increase of  or over the same period of cost of goods sold for the years ended december  and were  and  respectively  which represented and of net product sales  respectively 
research and development expenses were  for the year ended december   representing an increase of  or over the prior year  due primarily to higher personnel costs 
selling  general and administrative expenses for the year ended december  were  representing an increase of  or over the prior year 
the increase in selling general and administrative expenses was due primarily to increased personnel and legal costs associated with establishing the infrastructure required to manufacture and market the company s products globally 
interest and miscellaneous income 
interest expense was  for the year ended december   which represented a decrease of  over the prior year 
interest and miscellaneous income for the year ended december  was  representing an increase of  over the prior year  due to higher average cash and investment balances 
results of operations for the years ended december  and revenues 
total revenues for the year ended december  were  representing an increase of  or from the same period of net product sales for the year ended december  were  representing an increase of  or over the same period in this increase was due primarily to higher sales of synvisc in canada and sweden and from new sales of hylaform in certain european countries 
additionally  skin care product sales increased  or primarily resulting from the timing of orders 
sales of skin care products to the company s distributor  amerchol  represented of total skin care sales 
income from licenses  royalties  research contracts and grants were  in  an increase of  or from and represented of total revenues 
this increase was due primarily to the receipt of non refundable fees  which amounted to  for the year ended december   representing an increase of  over the same period of included in license fees for the year ended december   were up front payments from collagen corporation and boehringer ingelheim of  and  respectively 
included in license fees for the year ended december  was an up front payment from rpr of  costs and expenses 
total costs and expenses were  for the year ended december   representing an increase of  or over the same period of cost of goods sold for the years ended december  and were  and  respectively  which represented and of sales for the years ended december  and  respectively 
research and development expenses were  for the year ended december   representing an increase of  or over the prior year  due primarily to higher consulting costs 
selling  general and administrative expenses for the year ended december  were  representing an increase of  or over the prior year  due primarily to higher legal costs associated with patents and trademarks 
interest and miscellaneous income 
interest expense was  for the year ended december   which represented an increase of  over the prior year 
interest and miscellaneous income for the year ended december  was  representing an increase of  over the prior year  due to higher average cash and investment balances 
additionally  the increase in interest income was offset by a nonrecurring payment of  included in miscellaneous income during relating to a reimbursement for promotional materials 
income taxes provisions for federal or state income taxes were not necessary for the year ended december  in and  the company recorded federal and state tax provisions totaling  and  respectively  primarily for federal alternative minimum and state taxes 
the company has provided a full valuation allowance on the deferred tax assets due to the uncertainty of realization 
liquidity and capital resources the company had cash and cash equivalents of  at december  the company invests its excess cash in us government securities and  accordingly  any security purchased with a maturity of less than three months is classified as cash and cash equivalents 
as of december  all of the company s cash and cash equivalents were held in operating and money market accounts 
the company s operations over the past three years have been financed primarily from non refundable up front and milestone license fee payments from corporate partners  the utilization of the company s cash and investments  and the private placement of equity securities 
over the past three years  the company has received funding of  from the private placement of equity securities and  from non refundable license fee payments 
for the year ended december  the company had positive cash flow from operations of  which was primarily due to non recurring fees received during the year of  offset by cash outflows related to increased working capital levels needed to support synvisc launches 
in the company invested  in property  plant and equipment  primarily associated with building manufacturing capacity in the us and an increase in capacity of the canadian manufacturing facility 
the company continues to lease a  square foot building in new jersey in which the manufacturing capacity will reside 
the company has an option to acquire this building at a price of approximately  should the company not exercise its option in  the landlord has the right to require the company to purchase this building for approximately the same price 
the company also plans to relocate its executive and administrative offices and research and development laboratories to this building upon the expiration in of the company s lease on its current headquarters in new jersey 
additionally  the company received  in from the exercise of company stock options and  from the sale of common stock to certain officers of the company 
the company utilized  in funds to repurchase  shares of common stock from one of its distribution partners 
in  approximately  of the  invested in property  plant and equipment was spent on manufacturing capacity in the united states 
during  the company expects to invest an additional  to increase capacity at its united states location 
in addition  the company intends to build new laboratories and administrative offices to house its world headquarters as part of the same project at an estimated cost of  and  respectively 
the company expects to complete the laboratories and administrative offices by the summer of the company plans to seek lease and mortgage financing which  if obtained  could fund a portion of these capital costs 
during  the company also expects to utilize cash for the start up of its manufacturing capacity in the us  including  but not limited to  funds for payroll and benefits  training and development  materials and supplies  and working capital requirements 
the company also expects to incur higher expenses in associated with developing its internal infrastructure to support the administration of its various distribution agreements and expanded global operations 
the company believes that its capital needs  start up costs  and higher operating expenses will be supported by its operations  existing cash position  up front license fee payments from the potential completion of additional distribution agreements  milestone payments from existing corporate partners and potential financing arrangements 
in june  the fasb issued statement of financial accounting standards no 
reporting comprehensive income which establishes standards for reporting and display of comprehensive income and its components in a full set of financial statements 
the company is required to adopt this standard in and believes the principal additional component of comprehensive income that will be required to be disclosed is foreign currency translation 
in june  the fasb issued statement of financial accounting standards no 
disclosures about segment of an enterprise and related information which establishes standards for the way that public enterprises report information about operating segments  geographic areas  products and major customers 
the company is required to adopt this standard in and is currently evaluating the impact of this standard 
contingent liability in august  the company received a notice from the pennsylvania department of environmental resources der that it is one of approximately  potentially responsible parties prps that may have clean up responsibility at the industrial solvents and chemical company site in york haven  pennsylvania the site 
during the late s  the company  through a licensed waste disposal transport company  shipped industrial solvents to the site  which was operating as a recycling facility 
the der reviewed hazardous waste found at the site as well as the der s own records in order to identify additional prps and to quantify each prp s volumetric contributions 
the company is a member of a steering committee that consists of many prps 
although neither the total clean up cost nor the portion of the total clean up cost assigned to each prp has been determined  the company estimated  based upon the advice of a consultant  that its liability would be approximately  further  the same consultant has reported to the company that there is less than a chance that its liability might exceed  during the second quarter of the company paid its first assessment for clean up costs of  additionally  the company paid  during the first quarter of  therefore  the reserve at december  was  the steering committee for the prps has prepared a buy out proposal pursuant to a consent order with the der 
this buy out proposal identifies each prp s assigned portion of assumed total clean up costs 
the company s assigned portion of assumed clean up costs within the proposal is currently less than its reserve  however there can be no assurance that the proposal will be accepted 
when the final remedy is selected by the der  the company plans to settle out of the matter pursuant to the buyout proposal 
the company will monitor this situation and make any necessary adjustments to the reserve once additional information is available 
year the year issue is the result of computer programs being written using two digits rather than four to define the applicable year 
some computer programs that have time sensitive software may recognize a date using as the year rather than the year this could result in a system failure or miscalculations causing disruptions of operations  including a temporary inability to process transactions  send invoices  or engage in normal business and operating activities 
the company believes that its financial and operational systems  with limited modifications  will function properly with respect to dates in the year and thereafter 
the company estimates that the costs associated with the year issue will be insignificant  and as such will not have a material impact on the company s financial position or operating results 
there can be no assurance that the company s marketing partners and suppliers will not have year issues 

